Your browser doesn't support javascript.
loading
Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer
Martín, M; Hinojar, A; Cerezo, L; García, J; Lopez, M; Prada, J; Marín, A; Gamallo, C.
Afiliación
  • Martín, M; Instituto de Investigación Hospital de La Princesa. Department of Radiation Oncology. Madrid. Spain
  • Hinojar, A; Instituto de Investigación Hospital de La Princesa. Department of Otorhinolaryngology. Madrid. Spain
  • Cerezo, L; Instituto de Investigación Hospital de La Princesa. Department of Radiation Oncology. Madrid. Spain
  • García, J; Hospital Universitario Infanta Sofía. Department of Otorhinolaryngology. San Sebastián de los Reyes. Spain
  • Lopez, M; Instituto de Investigación Hospital de La Princesa. Department of Radiation Oncology. Madrid. Spain
  • Prada, J; Instituto de Investigación Hospital de La Princesa. Department of Otorhinolaryngology. Madrid. Spain
  • Marín, A; Instituto de Investigación Hospital de La Princesa. Department of Radiation Oncology. Madrid. Spain
  • Gamallo, C; Instituto de Investigación Hospital de La Princesa. Department of Pathology. Madrid. Spain
Clin. transl. oncol. (Print) ; 18(8): 825-830, ago. 2016. tab, ilus, graf
Article en En | IBECS | ID: ibc-154058
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
Background: Aldehyde dehydrogenase isoform 1 (ALDH1) has been shown to be a marker of cancer stem cells (CSCs). These stem cells may be responsible for tumour perpetuation as well as local and distant invasion. Several studies have shown that CSCs are more chemoradiotherapy (CRT)-resistant and may be responsible for tumour recurrence. Other studies, in contrast, have found ALDH1 expression to be indicative of a better prognosis. Methods: We retrospectively evaluated 84 patients diagnosed and treated for laryngeal cancer between 2006 and 2011. All patients underwent curative-intent radiotherapy or CRT at our institution. 57 of the 84 tumour samples contained sufficient material for ALDH1 assessment. Results: ALDH1 expression was detected in 17.5 % (10/ 57) of the tissue samples. None of the tumours from stage I patients tested positive for ALDH1. The relapse rate in ALDH1 + patients was 10 versus 51.2 % for ALDH1-. No differences in overall survival were observed between the groups; however, disease-free survival was 90 % for the ALDH1 ? group versus 48.9 % for ALDH1- patients (p = 0.034). Conclusion: The patients in this study with ALDH1 ? tumours had better outcomes than their counterparts with ALDH1- tumours. This finding suggests that not all CSCs are resistant to conventional cancer treatments. It may also imply that new methods of correctly identifying these cells are needed (AU)
RESUMEN
No disponible
Asunto(s)
Buscar en Google
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Inmunohistoquímica / Neoplasias Laríngeas / Aldehído Deshidrogenasa Tipo de estudio: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2016 Tipo del documento: Article
Buscar en Google
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Inmunohistoquímica / Neoplasias Laríngeas / Aldehído Deshidrogenasa Tipo de estudio: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2016 Tipo del documento: Article